CV Therapeutics Lets Innovex Do the Legwork--and Pay for Some of It, Too
Contract Sales Organizations have moved past their rent-a-rep past and are now trying to market themselves as full service marketing outsourcers which provide alternatives to co-marketing and outlicensing.. Innovex's recent deal with CV therapeutics, is a case-in-point and may provide a model for biotechs--and even some pharmaceutical companies--to follow in launching products on their own without incurring huge fixed costs.
You may also be interested in...
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.